Drug Trial Radar · NCT03005782
Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers
Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
333
Actual
Start
Nov 7, 2016
Primary completion
Apr 2, 2024
Study completion Apr 2, 2024
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- First posted
- Dec 29, 2016
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objectives in the dose escalation phase are to evaluate safety and pharmacokinetics (PK) in order to determine the selected dose level(s) for expansion of REGN3767 as monotherapy and in combination with cemiplimab in patients with advanced malignancies, including lymphoma. The primary objectives in the dose expansion phase are to assess preliminary anti-tumor activity of REGN3767 alone and in combination with cemiplimab (separately by cohort) as measured by objective response rate (ORR).
Conditions
- Malignancies
Interventions
REGN3767Drug
cemiplimabDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of dose limiting toxicities (Dose Escalation Phase)Time frame: Baseline to 28 days
- Rate of adverse events (Dose Escalation Phase)Time frame: Baseline to 51 weeks
- Rate of serious adverse events (Dose Escalation Phase)Time frame: Baseline to 51 weeks
- Occurrence of death (Dose Escalation Phase)Time frame: Baseline to 51 weeks
- Number of patients with laboratory abnormalities (grade 3 or higher per Common Terminology Criteria for Adverse Events [CTCAE]) (Dose Escalation Phase)Time frame: Baseline to 51 weeks
- Area under the curve (AUC) computed from time zero to the time of the last concentration [AUCall] (Primary: Dose Escalation Phase; Secondary: Dose Expansion Phase)Time frame: Baseline to 51 weeks
- AUCall-to-dose ratio [AUCall/Dose] (Primary: Dose Escalation Phase; Secondary: Dose Expansion Phase)Time frame: Baseline to 51 weeks
- AUC from time zero extrapolated to infinity [AUCinf] (Primary: Dose Escalation Phase; Secondary: Dose Expansion Phase)Time frame: Baseline to 51 weeks
- AUCinf-to-dose ratio [AUCinf/dose] (Primary: Dose Escalation Phase; Secondary: Dose Expansion Phase)Time frame: Baseline to 51 weeks
- AUC computed from time zero to the time of the last positive concentration [AUClast] (Primary: Dose Escalation Phase; Secondary: Dose Expansion Phase)Time frame: Baseline to 51 weeks
- AUClast-to-dose ratio [AUClast/dose] (Primary: Dose Escalation Phase; Secondary: Dose Expansion Phase)Time frame: Baseline to 51 weeks
- Clearance [CL] (Primary: Dose Escalation Phase; Secondary: Dose Expansion Phase)Time frame: Baseline to 51 weeks
- Maximum Plasma Concentration [Cmax] (Primary: Dose Escalation Phase; Secondary: Dose Expansion Phase)Time frame: Baseline to week 51
- Cmax-to-dose ratio [Cmax/dose] (Primary: Dose Escalation Phase; Secondary: Dose Expansion Phase)Time frame: Baseline to 51 weeks
- Last positive (quantifiable) concentration [Clast] (Primary: Dose Escalation Phase; Secondary: Dose Expansion Phase)Time frame: Baseline to 51 weeks
- Mean residence time extrapolated to infinity [MRTinf] (Dose Escalation Phase)Time frame: Baseline to 51 weeks
- Mean residence time when the drug concentration profile is based on values up to and including the last positive concentration [MRTlast] (Primary: Dose Escalation Phase; Secondary: Dose Expansion Phase)Time frame: Baseline to 51 weeks
- Observed terminal half-life [t1/2] (Primary: Dose Escalation Phase; Secondary: Dose Expansion Phase)Time frame: Baseline to 51 weeks
- t1/2 beta (Primary: Dose Escalation Phase; Secondary: Dose Expansion Phase)Time frame: Baseline to 51 weeks
- Time of the last positive (quantifiable) concentration [tlast] (Primary: Dose Escalation Phase; Secondary: Dose Expansion Phase)Time frame: Baseline to 51 weeks
- Time to Cmax [tmax] (Primary: Dose Escalation Phase; Secondary: Dose Expansion Phase)Time frame: Baseline to 51 weeks
- Volume of distribution at steady state [Vss] (Primary: Dose Escalation Phase; Secondary: Dose Expansion Phase)Time frame: Baseline to 51 weeks
- Volume of distribution of the terminal phase [Vz] (Primary: Dose Escalation Phase; Secondary: Dose Expansion Phase)Time frame: Baseline to 51 weeks
- Objective response rate based on RECIST 1.1 for Solid Tumors (Dose Expansion phase)Time frame: Baseline to 51 weeks
- Objective response rate by Lugano criteria for Lymphoma (Dose Expansion Phase)Time frame: Baseline to 51 weeks
Locations
43 sites in 5 countries. Site status is shown where the registry gives one.
California Cancer Associates for Research and Excellence
Encinitas, California
California Cancer Associates For Research And Excellence
Fresno, California
University of California San Diego (UCSD)
La Jolla, California
The Angeles Clinic
Los Angeles, California
University of California Davis Health Systems
Sacramento, California
California Pacific Medical Center (CPMC)
San Francisco, California
University of Colorado Cancer Center
Aurora, Colorado
Lombardi Comprehensive Cancer Center - MedStar Georgetown University Hospital
Washington D.C., District of Columbia
Miami Cancer Institute
Miami, Florida
Orlando Health, Inc
Orlando, Florida
Winship Cancer Institute at Emory University
Atlanta, Georgia
University of Kansas Clinical Research Center
Fairway, Kansas
Dana Farber Cancer Institute
Jamaica Plain, Massachusetts
Henry Ford Health Hospital
Detroit, Michigan
Cancer and Hematology Centers of Western Michigan
Grand Rapids, Michigan
Washington University in Saint Louis
St Louis, Missouri
John Theurer Cancer Center, Hackensack University Medical Center
Hackensack, New Jersey
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey
New Mexico Cancer Care Alliance-UNM Cancer Center
Albuquerque, New Mexico
Roswell Park Cancer Institute
Buffalo, New York
Northwell Health-Monter Cancer Center
Lake Success, New York
Laura & Isaac Perlmutter Cancer Center
New York, New York
Columbia University
New York, New York
Memorial Sloan-Kettering Cancer Center
New York, New York
Levine Cancer Institute
Charlotte, North Carolina
University Hospitals Seidman Cancer Center and Case Western Reserve University
Cleveland, Ohio
Stephenson Cancer Center
Oklahoma City, Oklahoma
Rhode Island Hospital
Providence, Rhode Island
Hollings Cancer Center - Medical University of South Carolina
Charleston, South Carolina
Sarah Cannon Research Institute
Nashville, Tennessee
The University of Texas MD Anderson Cancer Center
Houston, Texas
South Texas Oncology and Hematology
San Antonio, Texas
Virginia Cancer Care Specialist, PC
Fairfax, Virginia
Royal Brisbane and Women's Hospital
Brisbane, Australia
Peter Maccallum Cancer Centre (PMCC)
Melbourne, Australia
The University of Western Australia - The Queen Elizabeth II Medical Centre (QEIIMC) - Sir Charles Gairdner Hospital (SCGH)
Perth, Western Australia, Australia
St. Vincents University Hospital
Dublin, Ireland
Seoul National University Hospital
Seoul, South Korea
Severance Hospital, Yonsei University Health System
Seoul, South Korea
Asan Medical Center
Seoul, South Korea
Showing 40 of 43 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.